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Abstract
 
Preeclampsia is a serious complication of pregnancy in which the fetus receives an inadequate
supply of blood due to failure of trophoblast invasion. There is evidence that the condition has
an immunological basis. The only known polymorphic histocompatibility antigens on the fetal
trophoblast are HLA-C molecules. We tested the idea that recognition of these molecules by
killer immunoglobulin receptors (KIRs) on maternal decidual NK cells is a key factor in the de-
velopment of preeclampsia. Striking differences were observed when these polymorphic ligand:
receptor pairs were considered in combination. Mothers lacking most or all activating KIR (AA
genotype) when the fetus possessed HLA-C belonging to the HLA-C2 group were at a greatly
increased risk of preeclampsia. This was true even if the mother herself also had HLA-C2, indi-
cating that neither nonself nor missing-self discrimination was operative. Thus, this interaction
between maternal KIR and trophoblast appears not to have an immune function, but instead
plays a physiological role related to placental development. Different human populations have a
reciprocal relationship between AA frequency and HLA-C2 frequency, suggesting selection
against this combination. In light of our findings, reproductive success may have been a factor in
the evolution and maintenance of human HLA-C and KIR polymorphisms.
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Introduction
 
Although the fetus is allogeneic to its mother, there is little
evidence that alloimmune interactions at the maternal–fetal
interface in the uterine wall can compromise human preg-
nancy outcome. Most attention has been given to possible
maternal T cell responses to fetal histocompatibility or
other antigens. However, T cells are a minor component
of the immune cells in the early pregnancy decidua, and
placental trophoblast cells do not express the strong histo-
compatibility antigens, HLA-A, -B, or -D (1). Instead,
there is a profusion of CD56
 
bright
 
 NK cells that are in close
contact with the allogeneic extravillous trophoblast (EVT)
cells. These invade the decidua, subjacent myometrium,
and the walls of the spiral arteries during the first half of
human pregnancy (2). EVT expresses a unique combina-
tion of three MHC class I molecules: HLA-G, HLA-E, and
HLA-C (3, 4, 5). Of these, only HLA-C is polymorphic,
and the paternal allele is expressed on the trophoblast cell
surface. Therefore, in terms of allorecognition in the context
of placentation, trophoblast HLA-C is the relevant MHC
class I molecule to consider.
NK cells are effector lymphocytes that act by production
of cytokines and chemokines. They express a diverse com-
plement of receptors mediating both activating and inhibitory
signals (6). Uterine CD56
 
bright
 
 NK cells express a variety of
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these receptors, including the killer immunoglobulin re-
ceptor (KIR) family that includes members known to rec-
ognize HLA-C molecules (7). The KIR multigene family
exhibits an extensive degree of diversity, achieved by a
combination of presence or absence of particular genes
combined with allelic polymorphism of individual KIR
genes. This means that almost all unrelated individuals have
a different KIR genotype (7, 8, 9). On the basis of gene
content, two distinct KIR haplotypes can be distinguished,
termed A and B. The A haplotype has seven KIR loci with
only one activating receptor, KIR2DS4. However, the
most common allele of KIR2DS4 has a deletion so individ-
uals with two A haplotypes generally have no activating re-
ceptors. The B haplotypes are mainly characterized by the
presence of extra loci that are not present in the A haplo-
type, most of which encode activating receptors (KIR2DS1,
2, 3, 5, and KIR3DS1) as well as two inhibitory receptors,
KIR2DL2 and KIR2DL5. When considering HLA-C
molecules as ligands for KIR receptors on NK cells, all
HLA-C allotypes can be grouped into two major KIR
epitopes, C1 and C2, on the basis of a dimorphism at posi-
tion 80 of the 
 

 
1 domain (10, 11). Group C1 (HLA-C
 
asn80
 
)
are ligands for inhibitory KIR2DL2/3 and activating
KIR2DS2 and group C2 (HLA-C
 
lys80
 
) are ligands for in-
hibitory KIR2DL1 and activating KIR2DS1. Other acti-
vating KIR2DS receptors (KIR2DS3, 2DS4, and 2DS5)
with very similar sequences may also bind HLA-C mole-
cules (7, 8, 9).
Uterine NK (uNK) cells are phenotypically and func-
tionally distinct from NK cells in peripheral blood (2).
From gene expression studies, a case has been made that
uNK cells are a distinct NK cell lineage (12), although an
alternative explanation could be differentiation in the unique
decidual microenvironment. Functionally, their most likely
role is to modify the uterine spiral arteries to increase the
blood supply to the feto-placental unit. In humans, this
could occur by NK cells influencing the extent of tropho-
blast invasion into the arterial wall, whereas in mice their
effect may be directly on the vessels. In keeping with this,
mice with no uNK cells do not show the normal vascular
adaptations associated with pregnancy (13, 14). The phe-
notype of decidual NK cells is skewed toward a higher pro-
portion expressing KIRs with specificities for HLA-C allo-
types than is found in peripheral blood from the same
individual (15). Moreover, because pregnancy is a natural
allograft, the mother could possess KIR genes for paternal
HLA-C allotypes that she herself does not have. Con-
versely, the fetus could lack HLA-C KIR ligands that are
present in the mother. The dominant influence of HLA-C
on NK recognition and the profusion of NK cells at the
implantation site indicate that maternal NK cell–tropho-
blast HLA-C interaction deserves particular attention.
Inadequate placentation and poor placental perfusion are
features of preeclampsia, a specific disorder of human preg-
nancy that is associated with a significant maternal mortality
and morbidity (16). Preeclampsia develops in stages, the
maternal systemic illness being a late manifestation of the
placental ischaemia that is secondary to the reduced utero-
placental blood flow (17). Thus, the primary pathological
defect in this disease is the failure of transformation of the
uterine spiral arteries (2, 18). Genetic studies in preeclamp-
sia have implicated a contribution from both maternal and
paternal genotypes. A family history in maternal relatives is
associated with a fourfold risk (19). Despite this, no con-
cordance is found in monozygotic twins (20). In popula-
tion-based studies, a contribution of both paternal as well as
maternal factors in the development of the disease is appar-
ent (21). That immune recognition is involved is suggested
by the increased risk in first pregnancies and in multiparae,
but only after changing partners (22). Importantly, there is
also a greatly increased risk in women who have received
donated oocytes (
 

 
30%; reference 23). In this scenario, the
fetus will share neither maternal haploid gene set with the
recipient mother.
We suggest that control of the fetal vascular supply line
may depend on the allogeneic interaction between maternal
KIR on uNK cells and paternal HLA-C expressed by tro-
phoblast. Therefore, uNK cell function during pregnancy is
likely to be influenced by a combination of two polymor-
phic sets of genes; the maternal KIR genotype as well as the
trophoblast (fetal) HLA-C allotypes. In this work, we have
tested this hypothesis and analyzed how maternal KIR and
fetal HLA-C genes combine to influence the risk of pre-
eclampsia and reproductive success. Our results indicate that
certain combinations of paternal and maternal innate im-
mune genes are unfavorable for placentation.
 
Materials and Methods
 
Patients.
 
DNA was obtained from the blood of 200 pregnant
women with preeclampsia and from 201 matched women who
had normal pregnancies. Cord samples or mouth swabs were ob-
tained from the babies for genomic DNA isolation. The women
were recruited from three hospitals in the United Kingdom: St.
James University Hospital (Leeds), John Radcliffe Hospital (Ox-
ford), and Addenbrooke’s Hospital (Cambridge). Informed writ-
ten consent and local Ethics Committees’ approval were ob-
tained. Preeclampsia was defined as new hypertension after week
20 of pregnancy (140/90 mm Hg) together with new proteinuria
 

 
300 mg/24 h.
 
DNA Isolation.
 
Maternal genomic DNA was isolated from
5 ml of blood using the QIAamp DNA Maxi Blood Kit
(QIAGEN), and the babies’ DNA was isolated from cord samples
after overnight incubation with proteinase K (Roche Diagnos-
tics), phenol/chloroform purification and ethanol precipitation.
Occasionally, mouth-swab samples were taken and processed
using whole genome amplification performed with N
 
15
 
 random
primers (24).
 
KIR Genotyping.
 
KIR genotyping was based on the primers
and methods described previously (reference 25 and the online
supplemental Materials and Methods, available at http://www.jem.
org/cgi/content/full/jem.20041214/DC1). The KIR genes were
typed for presence or absence by PCR-SSP using two pairs of
primers per gene or allele and choosing primers that gave relatively
short amplicons of 100–800 bp (Table S1, available at http://
www.jem.org/cgi/content/full/jem.20041214/DC1). Where there
were problems with specificity, primers with mismatched bases
next to the specific 3
 

 
 terminal base were used. Initially, PCR
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product identity was checked by sequencing. KIR genes typed
were 2DL1, 2DL2, 2DL3, 2DL5, 2DS1, 2DS2, 2DS3, 2DS4,
KIR1D (2DS4 allele with a 22-bp deletion), and 3DL3.
 
HLA-C Genotyping.
 
HLA-C typing was performed by the
Tissue Typing laboratories at Addenbrooke’s Hospital or by the
Anthony Nolan Trust. Medium resolution PCR-SSP or PCR-
SSOP was used for typing, and all HLA-C group C1 alleles could
be distinguished from group C2.
 
Statistical Analysis.
 
Frequency differences between the pre-
eclampsia and control groups were tested for significance using
two-by-two tables and Fisher’s Exact statistic test, and the magni-
tude of effect was estimated by odds ratios and their 95% confi-
dence intervals (Windows 11.0.0.2001; SPSS Inc.). Where multi-
ple tests were involved, the p-values are given as an indication of
possible associations, not as definitive analyses. This involves the
testing of the separate KIR genes and the separate subsets of
mother/child pairs with the mothers’ AA genotype. A linear
model with a logistic link was used to test the association be-
tween increasing numbers of activating KIR and reduction in
prevalence of preeclampsia (LogXact software; Cytel Software
Corp.). For all analyses, p-values were exact and two sided.
 
Online Supplemental Material.
 
The detailed methods of KIR
genotyping are presented in a table of the primers used (Table S1).
HLA-C allele frequencies in preeclampsia and control patients are
shown in Table S2. KIR genotypes found in control and pre-
eclampsia mothers are shown in descending order of frequency
(Table S3). The number of activating and inhibitory KIR is given
in Table S4. References relating to the online supplemental mate-
rial are included. Online supplemental material is available at http:
//www.jem.org/cgi/content/full/jem.20041214/DC1.
 
Results
 
The Frequencies of HLA-C Groups and Alleles Are Similar in
Preeclampsia Patients and Controls.
 
First, we analyzed the
frequency of HLA-C groups, C1 and C2, in preeclampsia
and control pregnancies. The HLA-C1 and C2 frequencies
in preeclampsia and control mothers and their babies were
not significantly different and were similar to the results
from an Irish population (Table I and reference 26). We
also evaluated whether individual HLA-C alleles were asso-
ciated with preeclampsia. All mothers and babies were
typed by medium resolution PCR-SSP and PCR-SSOP
down to allele level. There were no significant differences
in allele frequencies in preeclampsia patients (
 
n
 
 
 
 
 
200) and
their babies compared with the control mothers (
 
n
 
 
 
 
 
201)
and their babies (Table S2, available at http://www.jem.
org/cgi/content/full/jem.20041214/DC1).
 
The Frequency of the Maternal AA Genotype Is Increased in
Preeclampsia Pregnancies.
 
All mothers were also typed for
the KIR genes: inhibitory, 2DL1, 2DL2, 2DL3, 2DL5, and
3DL3; and activating, 2DS1, 2DS2, 2DS3, 2DS4, and 2DS5.
On the basis of the presence of activating receptors charac-
teristic of the B haplotypes, the mothers were designated as
having either an AA genotype or an AB/BB genotype. 25%
of our control population had two A haplotypes (AA geno-
type) in agreement with previous reports in caucasoid popu-
lations (8, 27). Considering all preeclampsia patients, there
was a statistically significant increase in the frequency of the
AA genotype to 35% (P 
 

 
 0.038, OR 
 

 
 1.59, CI 
 

 
 1.03–
2.45; Fig. 1 A). When individual KIR genes were analyzed,
several were less frequent in preeclampsia mothers but only
the KIR2DL5 gene frequency reached statistical significance
(Table II). Consistent with previous reports we identified
considerable variation in frequency of the KIR leading to a
great diversity in genotypes (reference 8 and Table S3, avail-
able at http://www.jem.org/cgi/content/full/jem.20041214/
DC1). A total of 48 genotypes could be identified, a few of
which were common but most were present in only one or
two individuals.
 
The KIR AA Genotype Is Significantly Increased in Pre-
eclampsia When the Fetus Has an HLA-C2 Gene.
 
Continu-
ing to work from our original hypothesis, we analyzed
combinations of maternal KIR genotypes with fetal HLA-C
subgroups C1 and C2 that are relevant to KIR2D recogni-
tion. We found that the increased frequency of the afore-
mentioned AA genotype was only found in mothers who
were presented by a C2 allotype in the fetus (Fig. 1 B).
This increase in frequency of AA genotype was seen even
 
Table I.
 
HLA-C Genotype Groups for Control and Preeclampsia Cases
 
Controls Preeclampsia
Control
 
a
 
(N. Ireland)
HLA-C groups Mother Fetus Mother Fetus Individuals
 
% (n 
 

 
 201) % (n 
 

 
 201 
 

 
 4)
 
b
 
% (n 
 

 
 200) % (n 
 

 
 201 
 

 
 10)
 
b
 
% (n 
 

 
 1,000)
 
1 
 

 
 1 50.6 (102) 45.3 (91) 44.0 (88) 45.5 (91) 43 (430)
1 
 

 
 2 36.9 (77) 44.3 (89) 44.0 (88) 43.0 (86) 46.4 (464)
2 
 

 
 2 12.5 (22) 10.4 (21) 12.0 (24) 11.5 (23) 10.6 (106)
C1 69.9 67.7 66.0 67.0 66.2
C2 30.1 32.3 33.0 33.0 33.8
 
a
 
This independent, large dataset confirms the frequencies in our control samples (reference 26).
 
b
 
Multiple births, only fetus no. 1 was counted.
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when the fetus was heterozygous for C2 (Fig. 1 B), indicat-
ing that the expression of C2 has a dominant effect in the
presence of C1. In contrast, if the fetus was homozygous
for HLA-C1, the frequency of the AA genotype in pre-
eclampsia was similar to controls (Fig. 1 B). Merging the data
from Fig. 1 B, to distinguish between pregnancies where a
fetal C2 is presented compared with those in which C1
only is presented, there was a highly significant difference
in the frequency of the maternal AA genotype when com-
bined with fetal C2 (P 
 
 
 
0.001; OR 
 

 
 2.38; CI 
 

 
 1.45–
3.90; Fig. 1 C).
We looked in detail at individual maternal KIR genes
that differed significantly between normal and preeclampsia
pregnancies. As we saw no effect in preeclampsia pregnan-
cies when only fetal C1 was present, we have omitted these
patients (Table II). Most of the B haplotype KIRs were
present at significantly lower frequencies in these mothers
as would be expected from the AA genotype frequencies.
To test whether the number of activating receptors (char-
acteristic of the B haplotypes) possessed by the mother was
associated with preeclampsia, we used a linear logistic
model (Fig. 2, A and B). A 1.2-fold reduction in preva-
lence with each extra activating receptor was seen and this
was highly significant (P 
 

 
 0.0063). Data on the frequency
of KIR activating and inhibitory receptors in control and
preeclampsia mothers can be found in Table S4 (available at
http://www.jem.org/cgi/content/full/jem.20041214/DC1).
To summarize, we conclude that a combination of mater-
nal AA genotype with a fetal HLA-C2 group is associated
with preeclampsia and poor placentation.
 
Maternal KIR Recognition of Fetal HLA-C Is Not in Terms
of Nonself or Missing Self.
 
Next, we looked at whether the
C2 group was perceived as a nonself or missing self mole-
cule by the mother. The fetus may have an HLA-C allele
that is in a different group than the mother’s (Table III,
subsets a and b, “nonself”), or, in contrast, the mother
Figure 1. AA genotype and activating KIR frequencies in control and
preeclampsia mothers. (A) There was a significant difference in the AA
genotype frequencies between controls (white bar, n  201) and preeclamp-
sia patients (black bar, n  200). *, P  0.038. (B) The AA genotype fre-
quencies in subsets of patients with preeclampsia categorized depending
on the HLA-C groups 1 and 2 of mother (M) and fetus (F) (see Table III
for details and patient numbers). (a) M 1  1/F 1  2. *, P 5 0.005. OR 
3.22; CI  95%; 1.49–6.98. (b) M 2  2/F 1  2. *, P  0.034. (c) M
1  2/F 1  1. (d) M 1  2/F 2  2. (e) M 1  1/F 1  1. (f) M 1 
2/F 1  2. *, P  0.011. (g) M 2  2/F 2  2. The subsets in which the
fetus had a C2 allotype were a, b, d, f, and g. The subsets in which the fe-
tus only had a C1 allotype were c and e. The subset in which C2 was ab-
sent from the mother, but present in the fetus, was a. The subsets with
both mother and fetus having C2 were b, d, f, and g. Subset g is an ex-
ception to the increase in frequency of maternal AA genotype when the
fetus had a C2 allotype but the numbers were small (n  6). (C) The pa-
tients from Fig. 1 A have been divided into two subsets as follows: those
in which the fetus presents a C2 allotype (n  109; *, P  0.001; OR 
2.38; 95% CI  1.45  3.90) and those in which the fetus only had a C1
allotype (n  91; NS).
Figure 2. (A) The addition of each activating receptor is associated
with a 1.2-fold reduction in prevalence. A linear logistic model was used
to relate the prevalence of preeclampsia to the numbers of activating re-
ceptors possessed by the mother (KIR2DS1, 2DS2, 2DS3, 2DS4wt, and
2DS5). Control pregnancies were compared with affected mothers pre-
sented with fetal C2 as before. The model suggests an approximate 1.2-fold
reduction in prevalence with each additional activating receptor. The
sample size for the mothers with five activating receptors was very small
(n  6 for control and preeclampsia mothers combined). (B) A multiplicative
model is a good fit to the data. A plot of the expected versus observed num-
bers of affected mothers with increasing numbers of activating receptors
shows that the logistic model provides a good fit.
 Hiby et al.
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could have an HLA-C allele that is in a group that the fetus
lacks (Table III, subsets c and d, “missing self”). In the re-
maining pregnancies, the fetus and mother will have HLA-C
from the same groups (Table III, subsets e, f, and g, “self”).
We assigned both preeclampsia and control pregnancies to
these three possible scenarios to see if any occurred more
frequently in preeclampsia compared with control preg-
nancies. There was no significant increase in risk with these
three groups. We infer that, in classical immunological
terms, the fetal C1 and C2 groupings of nonself, missing
self, and self, in relation to the mother, probably have no
effect on reproductive success.
When considering the effect of C2 in the fetus in combi-
nation with the maternal AA genotype, we attempted to
dissect whether the presence of C2 in the mother as well as
the fetus had any influence. The effect of a maternal AA
genotype was particularly striking when HLA-C2 was ab-
sent from the mother and was only present in the fetus
(Fig. 1 B, subset a). The frequency of the AA genotype in
the mother was 52% compared with 25% in controls (P 
 

 
0.005). Importantly, an increase in the frequency of the AA
genotype was seen even when the mother herself also pos-
sessed a C2 allele (Fig. 1 B). This indicates that the fetal
HLA-C molecules are probably not being perceived by the
maternal KIR in terms of nonself or missing self. Rather, it
suggests that it is the presence of the HLA-C2 molecules
on trophoblast (as opposed to fetal or maternal somatic
cells) that is important in KIR recognition.
 
Group 2 HLA-C Frequencies and AA Genotypes in Different
Populations.
 
Given the dramatic influence of the KIR AA/
HLA-C2 combinations on reproductive success, we investi-
 
Table II.
 
KIR Gene/Genotype Frequencies in Control and Preeclampsia Mothers and Those Preeclampsia Mothers Presented with Fetal C2 in 
Homozygous (2 
 

 
 2) or Heterozygous (1 
 

 
 2) Form
 
Gene/genotype Control mothers Preeclampsia mothers Preeclampsia subsets with fetal C2 (a, b, d, f, g)
 
a
 
% (n 
 

 
 201) % (n 
 

 
 200) % (n 
 

 
 109)
 
2DL2 53 (107) 52 (103) 40
 
b
 
 (44)
P 
 

 
 0.033
2DS1 47 (94) 38 (76) 34
 
b
 
 (37)
P 
 

 
 0.031
2DS2 53 (108) 52 (104) 42 (46)
P 
 

 
 0.058
2DS3 29 (58) 24 (47) 15b (16)
P  0.005
2DS5 39 (83) 32 (83) 33 (36)
P  0.179
2DL5 58 (116) 47b (94)
P  0.036
41b (45)
P  0.006
Genotype AA 25 (50) 35b (69)
P  0.038
44b (48)
P  0.001
The B haplotypes KIR, 2DL2, 2DL5, 2DS1, 2DS3, and 2DS5 all occur at lower frequency in the preeclampsia mothers presented with HLA-C2 as
compared with the controls.
aThe letters a, b, d, f, and g refer to the subsets in Table III and Fig. 1 B.
bSignificantly different frequencies between preeclampsia and control mothers.
Table III. HLA-C Groups C1 and C2 in Control and 
Preeclampsia Mother/Child Pairs Categorized as Nonself, Missing 
Self, and Self
HLA-C group
Subsets Mother Fetus Control Preeclampsia
% (n  201) % (n  200)
Nonself
a 1  1 1  2 18.4 (37) 15.5 (31)
b 2  2 1  2 7.0 (14) 9.0 (18)
Missing self
c 1  2 1  1 12.4 (25) 16.5 (33)
d 1  2 2  2 5.5 (11) 7.7 (15)
Self
e 1  1 1  1 32.3 (65) 29.0 (58)
f 1  2 1  2 19.9 (40) 19.5 (39)
g 2  2 2  2 4.5 (9) 3.0 (6)
There were no significant differences between numbers of control and
preeclampsia pairs within these categories.
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gated if their effects might be detectable at the population
level. According to the model we have presented, and as-
suming that preeclampsia is disadvantageous in any popula-
tion, we would predict an inverse relationship between the
population prevalence of HLA-C2 and AA genotypes. To
test this, we tabulated the relative frequencies of HLA-C2
and the KIR AA genotype in populations for which data
were available (Fig. 3 and references 26–35). There was an
apparent inverse relationship between HLA-C2 and AA
frequencies (correlation coefficient (r)  0.82). The more
frequent C2, the less frequent was the AA genotype. The
most obvious association of maternal KIR AA genotype
with HLA-C2 was seen in the two historically isolated pop-
ulations from Japan and the Australian Aborigines who rep-
resent the extreme ends of the spectrum.
Discussion
We have found that the combination of maternal KIR
AA genotype with a fetal HLA-C2 is associated with an in-
creased risk of preeclampsia. In this scenario, the C2 on
trophoblast will only engage the inhibitory KIR2DL1 re-
ceptor. Therefore, the simplest interpretation is that the
primary defect in preeclampsia is caused by too much inhi-
bition of uNK cells leading to poor trophoblast invasion
into the uterine arteries. Because there is no association
with preeclampsia in pregnancies where the fetus is ho-
mozygous for C1 with a maternal KIR AA genotype, it is
presumed that in this situation, the inhibitory signal is less
strong to uNK cells and trophoblast invasion is unaffected.
This hypothesis is supported by previous data on C1 and
C2 interactions with their relevant inhibitory KIR that
show a stronger interaction of KIR2DL1 with C2 than
KIR2DL2/3 with C1. Thus, analysis of the crystal struc-
tures of C1 and C2 with their cognate KIR ligands re-
vealed the KIR2DL1–C2 complex to be energetically more
favorable than the KIR2DL2–C1 complex (36). Binding
studies using KIR–Fc fusion proteins or surface plasmon
resonance also indicate stronger binding of KIR2DL1 to C2
allotypes (37, 38, 39). Clinically, HLA-C1 and C2 have
been shown to have diverse effects in both HLA-identical
stem cell transplantation, and Hepatitis C infection (40,
41). In both these settings, a stronger inhibition of C2 via
KIR2DL1 than C1 via KIR2DL3 could explain the differ-
ent outcomes.
In the situation in which the fetal C2 allotype is com-
bined with maternal activating KIR (AB/BB genotypes),
the strong inhibition generated by engagement of KIR2DL1
would be balanced by activating signals to uNK cells, which
results in better trophoblast invasion. In keeping with this,
we found that every additional activating KIR incremen-
tally decreases the incidence of preeclampsia when the fetus
has C2. Given the extreme diversity of the KIR B haplo-
types (7, 8), more patients will be needed to discern which
particular activating KIRs are important.
From our results, we would predict that the KIR AA ge-
notype–C2 combination would be selected against in pop-
ulations given the deleterious effect these genetic variables
have on reproductive success. Indeed, this seems to be the
case, so that we have noted populations with a high AA ge-
notype frequency have a low frequency of C2 alleles and
vice versa. Therefore, the selective pressures for optimum
reproductive performance could be a major factor in driv-
ing the evolution and maintenance of KIR and HLA-C
polymorphisms. In infectious disease, such as HIV, acquisi-
tion of activating KIR–HLA combinations has also been
shown to be advantageous (42). This must be offset by the
potential NK cell overexuberance of activating KIR that
could result in autoimmune disease as seen in psoratic ar-
thropathy (25) and rheumatoid arthritis (43), thus provid-
ing balancing selection for AA genotypes.
This association of maternal KIR AA–fetal C2 combina-
tion in preeclampsia is seen whether or not the mother her-
self has a C2 gene. Therefore, this interaction does not fit
the well-established models of nonself and missing self rec-
ognition. Because our results show that the essential interac-
tion is between maternal NK cell KIR and fetal trophoblast
HLA-C2 independent of the presence of maternal C2, this
implies that the C2 molecules displayed by trophoblast must
be special and distinct from those found on somatic cells.
We have preliminary evidence that this is indeed the case
(4, 44). For example, trophoblast HLA-C molecules are
found to occur both as 2m-associated forms and as free
heavy chains. Like HLA-G, trophoblast HLA-C could also
form dimers or oligomers and be unusually glycosylated
(45–48). Specificity of KIR interactions does depend on the
peptide bound to HLA-C (49, 50). These peptides are likely
to be different when derived from EVT because trophoblast
are extraembryonic cells with many unusual properties, such
as endogenous retroviral protein expression (51).
Previous studies have shown that both maternal and pa-
ternal genotypes contribute to the risk of developing pre-
eclampsia (21, 52). Our data now extend these epidemio-
logical findings by identifying for the first time some of the
genes involved. Despite the strong family history found in
Figure 3. KIR genotype AA and HLA-C group 2 frequencies in dif-
ferent populations. Most of the HLA-C and KIR data have been taken
from different cohorts within each population (references 26–35). The
correlation coefficient (r) was 0.82.
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maternal relatives (19), the lack of concordance in identical
twins indicates that maternal genes cannot be solely respon-
sible (20). Preeclampsia is essentially a disease of primi-
gravidae (53–55), and it is difficult to explain why a first
pregnancy protects against the development of the disease
in subsequent pregnancies with the same partner. NK cells
are not known to exhibit memory, but, if our model is cor-
rect, in subsequent pregnancies with the same AA-C2
combination, we would predict that weaker inhibition
would occur via KIR2DL1. A possible way to achieve this,
given that the maternal KIR genotype is fixed, is for fewer
KIR2DL1 cells to be present at the implantation site or a
reduced level of expression of KIR2DL1 in the second
pregnancy. This could result from diminished influx of
blood KIR2DL1 NK cells to the uterine mucosa. Alter-
natively, if KIR acquisition takes place in utero, a previous
pregnancy might affect this so that fewer KIR2DL1 cells
or cells with lower expression levels are generated. This is
obviously speculative, but we have found phenotypic dif-
ferences in KIR expression between decidual and blood
NK cells in the same woman (15), although it is not yet
clear how this relates to the KIR genotype or obstetric
history. How and why the decidual KIR phenotype is
different, given the genetically and temporally fixed KIR
phenotype of blood NK cells (56, 57), is unknown. Under-
standing this might explain why a first pregnancy protects
against preeclampsia in subsequent pregnancies with the
same father.
The KIRs specific for MHC-C (lineage III) are confined
to humans and the great apes (7). Interestingly, MHC-C is
seen in only half of orangutans and all are C1 group, indi-
cating that C2 is a later addition (58). Comparisons of these
KIR and MHC-C genes indicate that these two gene fam-
ilies may have coevolved (59). This coordinated evolution
in different species suggests that they perform specialized
functions such as defense against species-specific pathogens.
Our paper raises the question whether species differences in
placentation is another stimulus driving KIR and MHC
coevolution. The size of the human brain relative to body
weight far exceeds any other primate (60). During the early
stage of simian primate evolution, a discoid invasive hemo-
chorial type of placenta emerged. With this placental
model, the only way to further increase the blood supply
necessary for development of a larger brain was for EVT to
invade the arteries in the placental bed more vigorously
(61). This is a dangerous strategy and balancing mechanisms
must have evolved concomitantly to prevent uterine pene-
tration and maternal death. It is significant that preeclamp-
sia occurs only in humans and represents pregnancies
where the balance is tilted toward maternal protective
mechanisms resulting in placental ischaemia and frequently
low birth weight.
In conclusion, we have found that a combination of a
maternal AA genotype with an HLA-C2 group in the fetus
is significantly associated with preeclampsia. This means
that if the fetus expresses a C2 allotype, it is detrimental for
placentation for the mother to have no activating KIR.
The effect of HLA-C2 group in the fetus was seen even if
the mother also had an HLA-C2 allele, and, therefore, nei-
ther nonself nor missing self is operative. A logical exten-
sion of this conclusion is that HLA-C2 allotypes are dis-
played by trophoblast in some different form than on
somatic cells. That the KIR AA genotype and HLA-C2
frequencies are inversely related in populations supports the
notion that reproduction provides a selective pressure for
KIR and HLA-C diversity. These results open up new
ways of thinking about both the maternal–fetal interaction
and the functions of KIR and HLA-C genes in popula-
tions. Overall, the conclusion is that the interaction be-
tween maternal KIR on uNK cells and fetal HLA class I
molecules on trophoblast has a physiological function in
regulating the development of the placenta, rather than the
much-vaunted idea that it is a maternal immunological de-
fense reaction mounted against her allogeneic fetus. This
would be a new view of an old problem (62).
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